Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Mycol Med ; 27(2): 261-265, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28188050

RESUMO

Symptomatic candiduria often occurs in patients with indwelling bladder catheters or immunocompromised host. Isolation of Candida in urine in high-risk patients should primarily be considered as a marker for candidemia. Hematological and genitourinary malignancies are one of the main risk factors associated with Candida urinary tract infections (CUTI). Fluconazole is a choice for initial treatment of CUTI, but it is fluctuate depending on the patient's condition including renal failure, site of urinary infection and Candida species. Poor glomerular filtration is the main disadvantage echinocandins resulting in very low urinary concentrations. Therefore, echinocandins have prohibited their use in CUTI. Up to now, there are only 10 cases reported in the literatures with highly effective echinocandins in CUTI because of high concentrations in the tissue are needed to control invasive fungal disease. Herein, we report a candiduria followed by renal candidiasis caused by Candida albicans in a 6-year-old Iranian male with a history of Wilms tumor in left kidney. Direct examination of urine specimen revealed an infection due to budding yeast cells with numerous pseudohyphae and growths of C. albicans was reconfirmed by sequencing of ITS rDNA region. MICs in increasing order were as follows: caspofungin (0.016µg/ml), voriconazole (0.125µg/ml), amphotericin B (0.25µg/ml), itraconazole (0.5µg/ml) and fluconazole (2µg/ml). It seems that successful treatment with caspofungin owes achieved high renal tissue concentrations that are unrelated to glomerular filtration. In conclusion, predisposing factors for better outcome are more important than treatment of CUTI, therefore, management of UTI is essential for critically patients.


Assuntos
Candidíase/tratamento farmacológico , Equinocandinas/uso terapêutico , Neoplasias Renais/tratamento farmacológico , Lipopeptídeos/uso terapêutico , Infecções Urinárias/tratamento farmacológico , Tumor de Wilms/tratamento farmacológico , Antifúngicos/uso terapêutico , Candida/isolamento & purificação , Candidíase/complicações , Candidíase/urina , Caspofungina , Criança , Humanos , Irã (Geográfico) , Neoplasias Renais/complicações , Neoplasias Renais/microbiologia , Masculino , Resultado do Tratamento , Infecções Urinárias/complicações , Infecções Urinárias/microbiologia , Tumor de Wilms/complicações , Tumor de Wilms/microbiologia
2.
Eur Rev Med Pharmacol Sci ; 17(22): 3068-72, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24302188

RESUMO

BACKGROUND: Approximately 0.5-2% of upper respiratory tract infections in adults and 6-13% of viral upper respiratory tract infections in children are complicated by acute sinusitis. This study was aimed to evaluate the coadministration effect of fluticasone nasal spray (FNS) with amoxicillin for AS in children. MATERIALS AND METHODS: One hundred children 2 to 14 years of age with acute sinusitis referred to Shahid Mohammadi Pediatric Hospital in Bandar Abbas were randomly allocated into two equal intervention and control groups to receive amoxicillin with fluticasone nasal spray one puff twice daily for 14 days and amoxicillin 80 to 100 mg/kg/ day for 14 days respectively. RESULTS: Twenty one (42%) of children in intervention group were cured completely and 2 (4%) children in control group had complete recovery (p < 0.001). Symptom severity score was 22.98 ± 2.95 before treatment that reduced to 13.26 ± 3.20 after treatment (p < 0.001). CONCLUSIONS: Use of fluticasone can reduce the severity of symptoms of sinusitis in children.


Assuntos
Amoxicilina/administração & dosagem , Androstadienos/administração & dosagem , Antibacterianos/administração & dosagem , Anti-Inflamatórios/administração & dosagem , Sinusite/tratamento farmacológico , Doença Aguda , Administração Intranasal , Adolescente , Criança , Pré-Escolar , Feminino , Fluticasona , Humanos , Masculino , Método Simples-Cego
3.
Indian Pediatr ; 41(12): 1232-7, 2004 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-15623904

RESUMO

Four hundred and fifty three healthy children immunized with a course of hepatitis B vaccine beginning at birth were tested at 10-11 years of age for persistence of anti-hepatitis B-S antigen antibody (anti-HBs); and responses of children without protective antibody to different doses of hepatitis B vaccine booster were evaluated. Although nearly 42% of them were not seroprotected, but most of boosted subjects (87.3%) retained robust immunologic memory and rapidly retained a protective anti-HBs antibody titer of at least 10 IU/L after booster vaccination.


Assuntos
Vacinas contra Hepatite B/uso terapêutico , Hepatite B/prevenção & controle , Memória Imunológica , Formação de Anticorpos , Criança , Feminino , Humanos , Imunização Secundária , Masculino , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...